PACTN: A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens in Patients With Myelodysplastic Syndromes (MDS)
About the Protocols
To participate, patients will first be enrolled in PersImmune’s blood and marrow collection protocol to acquire the blood cells necessary to generate the immunized T cells. You can read more about the protocol here:
Learn about the Collection Protocol »
During the time the product is generated, the patient may receive standard therapy for MDS. If the patient fails therapy, relapses, or declines to receive standard therapy, he or she will be evaluated for the clinical trial of experimental T cell infusion. Learn about the Infusion Protocol »
How to Participate:
The PACTN trial is being conducted at the UC San Diego Moores Cancer Center MDS Center of Excellence under Dr. Rafael Bejar, MD/PhD, with an additional blood sample collection site at the Chao Family Comprehensive Cancer Center at UC Irvine under Dr. Deepa Jeyakumar, MD. Please download a letter for physicians which may help guide you and your physician in discussing whether this trial is right for you or someone you know.
For specific information on how to participate, please visit the UC San Diego Health clinical trial website for the PACTN trial to learn more.
Patients may be eligible to participate in the MDS clinical trial if they:
Are 18 years of age or older
Have suspected or diagnosed MDS, preferably higher risk
Are not receiving corticosteroids >10 mg Prednisone/day or equivalent or immunosuppressants